VSIG4 (Gene)

Organism:

Homo sapiens

Synonyms:CRIg, ENTREZ:11326, HGNC:17032, MIM:300353, NM_001100431, NM_001184830, NM_001184831, NM_001257403, NM_007268, NP_001093901, NP_001171759, NP_001171760, NP_001244332, NP_009199, V-set and immunoglobulin domain containing 4, VSIG4, XM_017029251, XP_016884740, Z39IG

Omim:OMIM:300353

Id:ENSG00000155659

Hgnc:HGNC:17032

Entrez:11326

Ensembl:ENSG00000155659

Description:V-set and immunoglobulin domain containing 4

This gene encodes a v-set and immunoglobulin-domain containing protein that is structurally related to the B7 family of immune regulatory proteins. The encoded protein may be a negative regulator of T-cell responses. This protein is also a receptor for the complement component 3 fragments C3b and iC3b. Alternate splicing results in multiple transcript variants. [provided by RefSeq, May 2010]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View VSIG4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with VSIG4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using VSIG4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for VSIG4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with VSIG4.

Results found

Linked to

	Label	Description
	GSE125862 2 V 1 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 0 V 2 IMATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 nifurtimox A-549 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220520 3 V 4 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 1 V 2 NIFURTIMOX HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680,GSE182683 7 V 13 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680,GSE182683 5 V 13 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 3 V 2 IMATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE125862 2 V 1 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE140322 0 V 2 IMATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193541 nifurtimox A-549 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE220520 3 V 4 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE189035 inositol 2 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE193541 1 V 2 NIFURTIMOX HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE182680,GSE182683 7 V 13 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE182680,GSE182683 5 V 13 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE140322 3 V 2 IMATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.